Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

Clicks: 297
ID: 119058
1993
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. Forty-nine children (mean age at enrollment, ā€¦
Reference Key
hc1993antimicrobialcontrolled Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Meissner HC;Fulton DR;Groothuis JR;Geggel RL;Marx GR;Hemming VG;Hougen T;Snydman DR;;
Journal Antimicrobial agents and chemotherapy
Year 1993
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8215279
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't Infant Comparative Study newborn risk factors Clinical Trial Randomized Controlled Trial immunoglobulins intravenous / adverse effects intravenous / therapeutic use* respirovirus infections / prevention & control* immunoglobulin a / analysis respiratory tract infections / microbiology intravenous respiratory syncytial viruses* infusions respiratory tract infections / prevention & control* d r snydman pmid:8215279 pmc188036 doi:10.1128/aac.37.8.1655 h c meissner d r fulton diseases / prevention & control premedication

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.